Unknown

Dataset Information

0

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

ABSTRACT: Effective treatments for advanced/recurrent head and neck squamous-cell carcinoma are limited. For cases not curable by conventional local therapies, the immune checkpoint inhibitor pembrolizumab shows modest response rates. Quad-shot, a hypofractionated palliative radiotherapy regimen (14.8 Gy in four twice-daily fractions), can provide symptomatic relief, contributes to local control and may potentiate the effects of immune checkpoint inhibitors. In this study, 15 patients with advanced/recurrent head and neck squamous-cell carcinoma will be treated with pembrolizumab combined with up to three administrations of quad-shot before cycles four, eight and 13. Outcomes include disease response, survival and treatment toxicity. Correlative multiomics analysis of blood and saliva will identify molecular biomarkers of response to immune checkpoint inhibitor and the immune-related impact of quad-shot. Clinical trial registration: This study (WFBCCC 60320) is registered on NCT04454489 (ClinicalTrials.gov).

SUBMITTER: Hughes RT 

PROVIDER: S-EPMC10463211 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer.

Hughes Ryan T RT   Gebeyehu Rediet R RR   Kalada John Mason JM   Lycan Thomas W TW   Frizzell Bart A BA   Kinney Rebecca D RD   D'Agostino Ralph B RB   Bunch Paul M PM   Triozzi Pierre P   Zhang Wei W   Furdui Cristina M CM   Porosnicu Mercedes M  

Future oncology (London, England) 20230518 22

Effective treatments for advanced/recurrent head and neck squamous-cell carcinoma are limited. For cases not curable by conventional local therapies, the immune checkpoint inhibitor pembrolizumab shows modest response rates. Quad-shot, a hypofractionated palliative radiotherapy regimen (14.8 Gy in four twice-daily fractions), can provide symptomatic relief, contributes to local control and may potentiate the effects of immune checkpoint inhibitors. In this study, 15 patients with advanced/recurr  ...[more]

Similar Datasets

Unknown Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 "QUAD shot" regimen for incurable head and neck cancer.
| S-EPMC7251877 | biostudies-literature
Unknown Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer.
| S-EPMC7692120 | biostudies-literature
Unknown Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer.
| S-EPMC10931206 | biostudies-literature
Unknown Combining Radiotherapy and Immunotherapy in Head and Neck Cancer.
| S-EPMC10452591 | biostudies-literature
Unknown Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.
| S-EPMC8480112 | biostudies-literature
Unknown Hypofractionated Radiotherapy for Palliation in Locally Advanced Head and Neck Cancer.
| S-EPMC5545959 | biostudies-other
Unknown Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date.
| S-EPMC7153996 | biostudies-literature
Unknown Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges.
| S-EPMC7886974 | biostudies-literature
Unknown Reirradiation using robotic image-guided stereotactic radiotherapy of recurrent head and neck cancer.
| S-EPMC4915543 | biostudies-literature
Unknown First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
| S-EPMC9700657 | biostudies-literature